PMID- 25165193
OWN - NLM
STAT- MEDLINE
DCOM- 20150902
LR  - 20220316
IS  - 1523-5866 (Electronic)
IS  - 1522-8517 (Print)
IS  - 1522-8517 (Linking)
VI  - 17
IP  - 2
DP  - 2015 Feb
TI  - The mTOR signaling pathway as a treatment target for intracranial neoplasms.
PG  - 189-99
LID - 10.1093/neuonc/nou164 [doi]
AB  - Inhibition of the mammalian target of rapamycin (mTOR) signaling pathway has 
      become an attractive target for human cancer therapy. Hyperactivation of mTOR has 
      been reported in both sporadic and syndromic (hereditary) brain tumors. In 
      contrast to the large number of successful clinical trials employing mTOR 
      inhibitors in different types of epithelial neoplasms, their use to treat 
      intracranial neoplasms is more limited. In this review, we summarize the role of 
      mTOR activation in brain tumor pathogenesis and growth relevant to new human 
      brain tumor trials currently under way using mTOR inhibitors.
CI  - (c) The Author(s) 2014. Published by Oxford University Press on behalf of the 
      Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: 
      journals.permissions@oup.com.
FAU - Pachow, Doreen
AU  - Pachow D
AD  - Department of Neuropathology, Otto-von-Guericke University Magdeburg, Magdeburg, 
      Germany (D.P., C.M.); Department of Neurology, Washington University School of 
      Medicine, St Louis, Missouri (D.H.G.); Department of Neuro-Oncology, Neurology 
      Clinic & National Center for Tumor Diseases, University of Heidelberg and German 
      Cancer Research Center, Heidelberg, Germany (W.W.).
FAU - Wick, Wolfgang
AU  - Wick W
AD  - Department of Neuropathology, Otto-von-Guericke University Magdeburg, Magdeburg, 
      Germany (D.P., C.M.); Department of Neurology, Washington University School of 
      Medicine, St Louis, Missouri (D.H.G.); Department of Neuro-Oncology, Neurology 
      Clinic & National Center for Tumor Diseases, University of Heidelberg and German 
      Cancer Research Center, Heidelberg, Germany (W.W.).
FAU - Gutmann, David H
AU  - Gutmann DH
AD  - Department of Neuropathology, Otto-von-Guericke University Magdeburg, Magdeburg, 
      Germany (D.P., C.M.); Department of Neurology, Washington University School of 
      Medicine, St Louis, Missouri (D.H.G.); Department of Neuro-Oncology, Neurology 
      Clinic & National Center for Tumor Diseases, University of Heidelberg and German 
      Cancer Research Center, Heidelberg, Germany (W.W.).
FAU - Mawrin, Christian
AU  - Mawrin C
AD  - Department of Neuropathology, Otto-von-Guericke University Magdeburg, Magdeburg, 
      Germany (D.P., C.M.); Department of Neurology, Washington University School of 
      Medicine, St Louis, Missouri (D.H.G.); Department of Neuro-Oncology, Neurology 
      Clinic & National Center for Tumor Diseases, University of Heidelberg and German 
      Cancer Research Center, Heidelberg, Germany (W.W.).
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20140827
PL  - England
TA  - Neuro Oncol
JT  - Neuro-oncology
JID - 100887420
RN  - 0 (Protein Kinase Inhibitors)
RN  - EC 2.7.1.1 (MTOR protein, human)
RN  - EC 2.7.11.1 (TOR Serine-Threonine Kinases)
SB  - IM
MH  - Animals
MH  - Brain Neoplasms/*drug therapy/enzymology
MH  - Clinical Trials as Topic
MH  - Glioblastoma/*drug therapy/enzymology
MH  - Humans
MH  - Meningioma/*drug therapy/enzymology
MH  - Protein Kinase Inhibitors/*administration & dosage
MH  - Signal Transduction/drug effects
MH  - TOR Serine-Threonine Kinases/*antagonists & inhibitors/*metabolism
MH  - Treatment Outcome
PMC - PMC4288522
OTO - NOTNLM
OT  - glioblastoma
OT  - mTORC1
OT  - mTORC2
OT  - meningioma
EDAT- 2014/08/29 06:00
MHDA- 2015/09/04 06:00
PMCR- 2016/02/01
CRDT- 2014/08/29 06:00
PHST- 2014/08/29 06:00 [entrez]
PHST- 2014/08/29 06:00 [pubmed]
PHST- 2015/09/04 06:00 [medline]
PHST- 2016/02/01 00:00 [pmc-release]
AID - nou164 [pii]
AID - 10.1093/neuonc/nou164 [doi]
PST - ppublish
SO  - Neuro Oncol. 2015 Feb;17(2):189-99. doi: 10.1093/neuonc/nou164. Epub 2014 Aug 27.